Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
LB
M&
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
Lepu BiopharmaDrug Combination Therapy
Merck & Co.Pembrolizumab
Clinical Trials (2)
Total enrollment: 63 patients across 2 trials
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Start: Jan 2026Est. completion: Dec 2029
Phase 2Not Yet Recruiting
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Start: Sep 2022Est. completion: Dec 202863 patients
Phase 2Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3h ago
Office Administrator
SystImmune
3h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
3h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
3h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
3h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 63 patients
2 companies competing in this space